Formiget

Formiget combines Budesonide, an inhaled corticosteroid that reduces airway inflammation, with Formoterol, a long-acting beta-2 agonist that provides sustained bronchodilation. This dual therapy addresses both inflammatory and bronchoconstrictive components of obstructive airways disease. Budesonide inhibits inflammatory mediators and eosinophil activity, while Formoterol relaxes bronchial smooth muscle via beta-2 receptor stimulation, offering 12-hour symptom control suitable for maintenance therapy in persistent asthma and COPD.

Key Benefits:

• Reduces asthma exacerbations and improves lung function
• Provides 12-hour bronchodilation for symptom control
• Anti-inflammatory action prevents airway remodeling
• Suitable for step-up therapy in uncontrolled asthma
• COPD symptom relief in patients with exacerbation history
• Once- or twice-daily maintenance dosing

How to Use

• Administration: Shake well; exhale fully, inhale deeply while actuating, hold breath 10 seconds, exhale slowly. Use spacer if coordination impaired.
• Dosage: Asthma: 1-2 puffs 1-2x daily; COPD: As prescribed for adults 18+. Rinse mouth after use to prevent thrush.
• Timing: Regular intervals; morning/evening preferred for twice-daily.
• Technique: Prime if new; clean mouthpiece weekly.
• Monitoring: Track symptoms, peak flow; adjust per physician.

Expert Tips from CureCart Direct:

• Never use as rescue; maintain separate short-acting inhaler.
• Rinse mouth post-inhalation to minimize oral candidiasis.
• Do not exceed prescribed doses; taper under guidance.
• Store at room temperature; protect from freezing/sunlight.
• Educate on proper technique via pharmacist demonstration.

Missed Dose: Take as soon as remembered unless near next—skip and resume. Do not double.

Overdose: Excessive beta-agonist may cause tachycardia, tremor—seek immediate care.

Primary Uses

• Regular asthma treatment in adults/adolescents 12+ years.
• Maintenance therapy for uncontrolled asthma on ICS + SABA.
• Continuation in patients controlled on ICS + LABA.
• Symptomatic COPD treatment in adults with FEV1 <70% predicted and exacerbation history.

Indications

Asthma (Adults & Adolescents 12+ years): Regular treatment where ICS+LABA combination appropriate:

• Patients not controlled with ICS + as-needed SABA.
• Patients controlled on both ICS + LABA.

COPD (Adults 18+ years): Symptomatic treatment in patients with FEV1 <70% predicted (post-bronchodilator) and exacerbation history despite regular bronchodilators.

Side Effects

Common:

• Oral candidiasis (thrush)
• Hoarseness, throat irritation
• Headache, tremor
• Tachycardia, palpitations

Less Common:

• Pneumonia risk in COPD
• Paradoxical bronchospasm
• Adrenal suppression (long-term high-dose)
• Bone density reduction

Serious/Rare:

• Hypokalemia, hyperglycemia
• Cardiovascular effects
• Allergic reactions

Rinse mouth to reduce local effects.

Warnings and Precautions

• Pregnancy/Lactation: Use if benefits outweigh risks; monitor fetal growth.
• Driving: May cause tremor—avoid until tolerated.
• Asthma: Not for acute relief; risk of masking worsening control.
• COPD: Increased pneumonia risk; monitor infections.
• Cardiovascular: Caution in heart disease, arrhythmias.
• Children: Not for <12 years in asthma; COPD adult-only.
• Other: Taper slowly; regular bone density checks in long-term use.

Contraindications

Do not use in:

• Hypersensitivity to components.
• Acute bronchospasm (use SABA instead).
• Primary treatment of status asthmaticus.
• Children <12 years for asthma indication.

Drug Interactions

• Beta-Blockers: Antagonize bronchodilation (avoid non-selective).
• CYP3A4 Inhibitors (e.g., ketoconazole): Increase corticosteroid exposure.
• Diuretics/Steroids: Enhanced hypokalemia.
• MAOIs/Tricyclics: Potentiate beta-agonist effects.

Storage/Disposal

Store at room temperature (15-30°C), away from heat, freezing, sunlight. Keep canister from fire; do not puncture. Discard per expiry or when empty. Pharmacist disposal guidance; childproof storage.

Doctor Review

Dr. Sara Malik, MBBS, FCPS – Consultant Pulmonologist “Formiget’s fixed-dose ICS/LABA combination leverages Budesonide’s topical anti-inflammatory potency with Formoterol’s rapid-onset, sustained bronchodilation, achieving synergistic control in persistent asthma and COPD phenotypes. Pharmacologically, Budesonide minimizes systemic glucocorticoid effects via high first-pass metabolism, while Formoterol’s dual beta-2/alpha-1 affinity provides efficient airway selectivity. Clinical positioning targets step-up from ICS monotherapy in asthma (GINA guidelines) and exacerbation-prone COPD (GOLD criteria), with FEV1 <70% threshold identifying volume-responsive obstruction. Pneumonia risk elevation in COPD underscores infection vigilance, alongside LABA monotherapy avoidance in asthma per black-box considerations.”

FAQs

Asthma age range? Adults and adolescents 12+ years for regular treatment.

COPD criteria? Adults 18+ with FEV1 <70% predicted and exacerbation history.

Rescue use? No; for maintenance only—keep SABA separate.

Mouth rinse necessary? Yes, prevents thrush from corticosteroid residue.

Pneumonia risk? Higher in COPD patients; monitor respiratory infections.

Related Tests: Spirometry (FEV1), peak flow, chest X-ray.

Quick Tips:

• Shake, inhale deeply, hold breath.
• Rinse mouth after each use.
• Spacer for optimal delivery.
• Track symptoms for dose review.

Disclaimer: This information is for educational purposes only and not a substitute for professional medical advice. Always consult a qualified physician before use. CureCart Direct ensures accurate details but cannot cover all interactions or precautions. Prices and availability subject to change. Last updated: October 15, 2025.